Evidence map›Paper›PMID 29236227›Full record

ArticlePurinergic signalling2018

Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension.

Charlotte Roy, Julie Tabiasco, Antoine Caillon, Yves Delneste, Jean Merot, Julie Favre, Anne Laure Guihot, Ludovic Martin, Daniele C Nascimento, Bernhard Ryffel and 4 more

Abstract read
In one paragraph

Article in Purinergic signalling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Ectonucleotidase Modulation of Lymphocyte Function in Gut and Liver.Frontiers in cell and developmental biology · 2020
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charlotte RoyMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Julie TabiascoCNRS UMR 6299, INSERM 892, CRCNA, University of Angers, Angers, France.
Antoine CaillonMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Yves DelnesteCNRS UMR 6299, INSERM 892, CRCNA, University of Angers, Angers, France.
Jean MerotL'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
Julie FavreMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Anne Laure GuihotMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Ludovic MartinMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Daniele C NascimentoCNRS, UMR 7355, Orleans, France.
Bernhard RyffelCNRS, UMR 7355, Orleans, France.
Simon C RobsonDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA.
Jean SévignyDépartement de microbiologie-infectiologie et d'immunologie, Faculté de Médecine, Université Laval, Québec City, QC, G1V 0A6, Canada.
Daniel HenrionMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France.
Gilles KauffensteinMITOVASC Institute - UMR CNRS 6015 INSERM U1083 University of Angers, Angers, France. gilles.kauffenstein@gmail.com.ORCID http://orcid.org/0000-0003-4994-8305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ectonucleoside triphosphate diphosphohydrolase-1, the major vascular/immune ectonucleotidase, exerts anti-thrombotic and immunomodulatory actions by hydrolyzing extracellular nucleotides (danger signals). Hypertension is characterized by vascular wall remodeling, endothelial dysfunction, and immune infiltration. Here our aim was to investigate the impact of arterial hypertension on CD39 expression and activity in mice. Arterial expression of CD39 was determined by reverse transcription quantitative real-time PCR in experimental models of hypertension, including angiotensin II (AngII)-treated mice (1 mg/kg/day, 21 days), deoxycorticosterone acetate-salt mice (1% salt and uninephrectomy, 21 days), and spontaneously hypertensive rats. A decrease in CD39 expression occurred in the resistance and conductance arteries of hypertensive animals with no effect on lymphoid organs. In AngII-treated mice, a decrease in CD39 protein levels (Western blot) was corroborated by reduced arterial nucleotidase activity, as evaluated by fluorescent (etheno)-ADP hydrolysis. Moreover, serum-soluble ADPase activity, supported by CD39, was significantly decreased in AngII-treated mice. Experiments were conducted in vitro on vascular cells to determine the elements underlying this downregulation. We found that CD39 transcription was reduced by proinflammatory cytokines interleukin (IL)-1β and tumor necrosis factor alpha on vascular smooth muscle cells and by IL-6 and anti-inflammatory and profibrotic cytokine transforming growth factor beta 1 on endothelial cells. In addition, CD39 expression was downregulated by mechanical stretch on vascular cells. Arterial expression and activity of CD39 were decreased in hypertension as a result of both a proinflammatory environment and mechanical strain exerted on vascular cells. Reduced ectonucleotidase activity may alter the vascular condition, thus enhancing arterial damage, remodeling, or thrombotic events.

Indexed as

AnimalsAntigens, CDApyraseArteriesEndothelial CellsHypertensionMaleMiceMice, Inbred C57BLMyocytes, Smooth MuscleAntigens, CDApyraseCD39 antigenAngiotensin IIATPCD39EctonucleotidaseHypertension

Identifiers

PMID29236227
PMCPMC5842157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.